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Zusammenfassung
Etwa zwei Drittel der Patienten mit paraneoplastischen
neurologischen Erkrankungen kommen zunächst zum
Neurologen, da der Tumor nicht bekannt ist. Aufgrund
der begleitenden Immunreaktion verhält sich dieser
Tumor relativ gutartig, und ist daher auch relativ schwer
zu diagnostizieren. Bei Patienten mit bereits bekanntem
Tumor ist das Neuauftreten oder die Verschlechterung
bestehender neurologischer Symptome immer ein Warn-
zeichen für ein Tumorrezidiv. In beiden Situationen ist
das Vorliegen von anti-neuronalen Antikörpern diagnos-
tisch sehr hilfreich, sie komplementieren andere dia-
gnostische Maßnahmen wie MRT, Liquor- und Elektro-
physiologie. Die Tumortherapie ist weiterhin die wich-
tigste therapeutische Maßnahme; eine begleitende
Immuntherapie sollte parallel dazu eingeleitet werden.
Die Fortschritte im Verständnis der autoimmunen Patho-
genese dieser Syndrome, insbesondere die Rolle zytoto-
xischer T-Zellen, werden hoffentlich bald zu effektiveren
Behandlungsmöglichkeiten führen.
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Abstract
In about two thirds of cases, patients with paraneoplastic
neurological disorders present to the neurologist with-
out a known tumor. Due to the ongoing immune respon-
se, this tumor tends to stay biologically relatively benign,
and therefore difficult to diagnose. In patients with a
known tumor, the neurological symptoms often precede
a tumor recurrence. In both scenarios, anti-neuronal anti-
bodies are an invaluable diagnostic help to the clinician,
and may be supplemented by other diagnostic tests such
as MRI, CSF, and electrophysiology. Tumor therapy re-
mains the mainstay of therapeutic options, although
early immune therapy must be started in parallel. It is
hoped that the recent fundamental advances in under-
standing the autoimmune pathology of these disorders,
especially the role of cytotoxic T cells, will eventually
lead to more effective treatment options.
Diagnosis of a Paraneoplastic Neurological Syndrome 
Nearly any neurological syndrome (central, peripheral, neuro-
muscular, muscular) may be of paraneoplastic etiology [1, 2].
Clinically it is of high therapeutic relevance to diagnose a
paraneoplastic etiology quickly and correctly, as this will alter
the management of the patient dramatically. Either, in a pa-
tient without a known tumor, that tumor must be identified
and treated, or in a patient with known tumor diagnosis, de-
velopment of a paraneoplastic neurological syndrome fre-
quently heralds tumor recurrence. 
Initially, the term paraneoplastic neurological disorders
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(PND) was coined for all non-metastatic neurological tumor
complications where a specific etiology – such as vascular, in-
fectious, metabolic, or treatment-related causes – could not be
defined. Since the detection of the first antibody specific for a
paraneoplastic etiology – the anti-Hu antibody – and descrip-
tion of its clinical relevance by Prof. Posner’s laboratory the
number of clinically relevant antibody reactivities as markers
of a paraneoplastic etiology has grown at the speed of about
one per year [1–3]. 
Clinical Suspicion
The first step in diagnosis relies on clinical skills leading to
early clinical suspicion. Here, it has become clear in recent
years that PND may not only follow the ‘typical’ subacute
time course, but may also be indolent (over years!) or sponta-
neously relapsing-remitting (cave: misdiagnosis multiple scle-
rosis!) [4, 5]. Furthermore, PND may present as a ‘typical’
neurological syndrome, such as LEMS (Lambert-Eaton myas-
thenic syndrome), cerebellar degeneration, or sensory neu-
ronopathy, but it may also be ‘atypical’, presenting as depres-
sion or memory disturbance (as in limbic encephalitis) or
pseudo-ileus (autonomic polyneuropathy) [6, 7]. 
Limbic Encephalitis 
According to a recent large series of 50 patients, diagnostic
criteria for a paraneoplastic limbic encephalitis (PLE) may be
(1) typical clinical symptoms (see below), (2) less than 4 years
to tumor diagnosis, (3) exclusion of other differential diag-
noses and (4) pathological results in CSF, MRI or EEG [6].
Most patients have a subacute progressive course. Symptoms
are short-term memory disturbance, epileptic seizures, acute
confusional syndrome, further psychiatric symptoms (person-
ality change, hallucination, depression), brainstem symptoms,
signs of hypothalamic involvement, cognition disturbance, and
signs of involvement of other neurological systems. In more
than half of all patients, a tumor is diagnosed only after onset
of symptoms. In 50% this was a lung tumor, 20% had a testic-
ular tumor, and 8% a breast tumor. Three quarters of all tu-
mors were growing only locally. All except one patient showed
pathological results in two of three investigations: MRI, CSF,
or measuring anti-neuronal antibodies [2, 8, 9].
Cerebellar Degeneration
A subacutely developing cerebellar syndrome in a woman
above age 50 is in almost two thirds of cases a paraneoplastic
cerebellar degeneration (PCD) [10]. Clinically, all patients
with PCD present in a similar way. Using serological analysis
of the associated anti-neuronal antibodies, the patients may
be sudivided into several subgroups (table 1). These sub-
groups differ in the associated tumors, course (neurological
stabilisation in anti-Yo, progression in anti-Hu), and regarding
survival. Anti-Hu patients show a median survival of 9–12
months, anti-Yo patients with breast cancer 100 months and
anti-Yo patients with other gynecological tumors 22 months
[8, 11, 12]. In patients who have a SCLC associated with PCD,
further diagnostic procedures should be performed to search
for an associated Lambert-Eaton myasthenic syndrome (i.e.
anti-VGCC and electrophysiology, see below) or the presence
of VGCC even in absence of LEMS [13, 14]. 
Sensory Neuropathy
The ‘classical’ paraneoplastic polyneuropathy is a sensory
neuronopathy (SN) as first described by Denny-Brown in
1948 [15]. Typically, these patients initially have an asymmetri-
cal and painful sensory neuropathy which evolves into typical
complete loss of proprioception. The pseudo-athetotic move-
ment of the hands and severe sensory ataxia is clinically im-
pressive and usually very severe. Mostly, anti-Hu antibodies
can be identified which have a specificity of 99% and a sensi-
Table 1. Antibody-defined subgroups of paraneoplastic cerebellar degeneration
Group Most frequent Sex Clinical symptoms Start of neurological Median survival
tumors associated symtoms
Anti-Yo breast, ovarian F>>M subacute, severe mostly before tumor diagnosis 100 mo if breast, 
22 mo if ovarian
Anti-Hu SCLC M>F additional symptoms of PEM / SN mostly before tumor diagnosis 12 months
PCD and LEMS SCLC M = F absent reflexes mostly before tumor diagnosis
(Ab neg.) 
Anti-CRMP5 /-CV2 SCLC, thymoma F>M subacute, severe, additional symptoms mostly before tumor diagnosis
of PEM /SN 
Anti-Tr Hodgkin’s disease M>F less severe, partly remitting mostly after tumor diagnosis
Anti-Ri breast F opsoclonus/ataxia before or after tumor diagnosis
PCA-2 lung M = F additional symptoms of PEM / SN mostly before tumor diagnosis
ANNA-3 SCLC additional symptoms of PEM / SN mostly before tumor diagnosis
Anti-Ma various F>M subacute, brainstem mostly before tumor diagnosis
Atypical or no Ab various F = M various before or after tumor diagnosis
Ab = Antibody; F = female; M = male; PCD = paraneoplastic cerebellar degeneration; LEMS = Lambert-Eaton myasthenic syndrome; 
PEM/SN = paraneoplastic encephalomyelitis / sensory neuropathy.
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tivity of 82% for a paraneoplastic sensory neuropathy [16].
Other less frequent antibodies are anti-CV2 or anti-am-
phiphysin.
Lambert-Eaton Myasthenic Syndrome (LEMS)
In about 60% of patients with LEMS an underlying tumor,
usually SCLC, rarely a lymphoma may be detected [17]. The
associated SCLC have a significantly better prognosis if
LEMS is present [18]. Unfortunately, no serological marker
for the paraneoplastic etiology exists. Anti-VGCC antibodies
are present in almost all patients with LEMS, and they do not
differentiate between the paraneoplastic and non-paraneo-
plastic forms. The prevalence of LEMS in SCLC is about 3%
Syndrome Antibody for Associated tumor

diagnosis paraneoplastic 
etiology
LEMS anti-VGCC n.a. SCLC
Subacute cerebellar anti-Hu SCLC, prostate
degeneration
anti-PCA-2 SCLC
anti-CRMP5/-CV2 SCLC, thymoma
ANNA-3 SCLC
anti-Yo ovary, breast
anti-Ta/Ma2 testis
anti-Ma miscellaneous
anti-Ri breast, lung
anti-Tr Hodgkin’s lymphoma
Opsoclonus/myoclonus (child) anti-Hu neuroblastoma
Dermatomyositis n.a. ovary, lung, pancreas
Opsoclonus/myoclonus (adult) anti-Ri breast, lung
anti-Hu SCLC, prostate
anti-Ma miscellaneous
anti-Ta/Ma2 testis
Subacute sensory neuropathy anti-Hu SCLC, prostate
anti-amphiphysin SCLC
ANNA-3 SCLC
anti-CRMP5/-CV2 SCLC, thymoma
Limbic encephalopathy anti-Hu SCLC, prostate
anti-Ta/Ma2 testis
ANNA-3 SCLC 
anti-CRMP5/-CV2 SCLC, thymoma
Extrapyramidal syndromes  anti-Hu SCLC, prostate
anti-Ta/Ma2 testis
anti-Ma various
anti-CRMP5/-CV2 SCLC, thymoma
Myasthenia gravis anti-AChR, anti-titin thymoma
anti-MUSK
Sensorimotor anti-Hu SCLC, prostate
peripheral neuropathy
anti-amphiphysin SCLC
anti-CRMP5/-CV2 SCLC, thymoma
Encephalomyelitis  anti-Hu SCLC, prostate
Visual loss  anti-Hu SCLC, prostate
anti-recoverin lung
Stiff-person syndrome anti-GAD anti-amphiphysin breast
n.a.: Not available; AChR: acetylcholine-receptor; GAD: glutaminic acid dehydrogenase; 
LEMS: Lambert-Eaton myasthenic syndrome; SCLC: small cell lung cancer; 
VGCC: voltage gated calcium channel.
Table 2. Clinically useful antibody reactivities
for identifying the paraneoplastic etiology of a
given neurological syndrome
and must not be overlooked as LEMS responds well to im-
munomodulatory therapy [19–21]. 
Anti-Neuronal Antibodies
In case of clinical suspicion of the presence of a PND, anti-
neuronal antibodies should be measured in the serum of the
patient. Which antibodies should be looked for, depends on
neurological syndrome (table 2). Here, only reactivities which
are markers for the paraneopalstic etiology are mentioned.
Antibodies such as anti-AChR, anti-VGCC or anti-VGKC are
clinically most relevant markers, but they are not specifically
associated with a paraneoplastic etiology. Depending on the
neurological syndromes, anti-neuronal antibodies must be
supplemented by other diagnostic tests such as MRI, CSF, or
electrophysiology. Combining these diagnostic options may
lead to a sensitivity of close to 100% for detecting a paraneo-
plastic etiology [6].
Anti-Hu Antibody
Since the initial description of anti-Hu, this first clinically fully
characterized paraneoplastic antibody has also turned out to
be the most frequent [3, 8, 22–24]. The anti-Hu antibody may
be associated with a central encephalomyelitis or a peripheral
neuropathy. Importantly, the associated tumors tend to be lim-
ited and show no metastases (other than to mediastinal lymph
nodes) [25]. Anti-Hu (at low titer) is also present in about
16% of patients with SCLC without neurological symptoms
[26]. In these patients, the anti-Hu is a positive predictor of
complete response to tumor treatment [27]. 
Anti-Yo Antibody
Anti-Yo defines a subgroup of patients with PCD and breast
or ovarian cancer (see above) and is the second most common
anti-neuronal reactivity [11, 12]. One of the antigens recog-
nized by anti-Yo sera is cdr2 (cerebellar degeneration-related
protein) which is mainly expressed in cerebellar Purkinje cells
and some tumors. 
Anti-Ma/Ta Antibody
This antibody reactivity has only been recognized recently [5,
9, 28]. The antibody reactivity to Ma proteins is highly specific
for a paraneoplastic etiology, and all patients react against the
immunodominant Ma2 protein. In an isolated anti-Ma2 reac-
tivity, patients tend to be younger and mainly have PLE asso-
ciated with a germ cell tumor of testis. A reactivity against
other Ma proteins (PNMA1, PNMA3) in addition to Ma2
identifies patients who are older, have a rhombencephalitis
and PCD associated with several different tumors [5, 9, 28].
The function of the Ma proteins is still unknown.
Anti-Tr Antibody
Named after the first descriptor Trotter rather than an index
patient [29], anti-Tr is found in PCD associated with
Hodgkin’s disease and reacts with cytoplasm of Purkinje cells
additionally showing a characteristic punctate pattern in the
molecular layer of the cerebellum [30, 31].  Most patients rec-
ognize a myc-associated zink finger protein that it is not the Tr
antigen [32]. Typically and in contrast to other paraneoplastic
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antibodies, the titer may turn negative during course of treat-
ment and may only be found in CSF and not in serum [31, 33].
Anti-CV2 Antibody / Anti-CRMP5 Antibody
Initially Honnorat et al. described anti-CV2 as a paraneoplas-
tic marker in 1996 [34]. Recently, the group of Lennon de-
scribed an anti-CRMP5 reactivity in 116 patients which prob-
ably constitutes the same antibody [35]. In the series of Yu et
al. [35], 26% had cerebellar ataxia, 25% dementia, 17% cra-
nial neuropathy, 11% chorea, 10% loss of taste or olfaction,
and 7% optic neuropathy. In 77% a lung tumor and in 6% a
thymoma had been identified.
Treatment
Treatment options include tumor therapy, symptomatic treat-
ment, and modulation of the immune system.
Tumor Therapy
In patients without known tumor but a highly likely paraneo-
plastic etiology finding the tumor is essential but may be diffi-
cult. As there is a biologically effective immune response
against the underlying tumors, the tumors may initially stay
locally or even histologically small [27]. If specific antibody re-
activities are present, they direct the tumor search to specific
organs. If a tumor is identified which does not fit the known
tumor pattern, this tumor should be checked for ‘atypical’ ex-
pression of the relevant antigen [8], and the possibility of a
second malignancy must be considered [23]. Recently, the use
of whole-body FDG-PET has been advocated for early tumor
diagnosis in patients with anti-Hu or clinically suspected PND
[36–38]. With all therapeutic approaches in PND it must be
kept in mind that the natural course may be fluctuating [5] or
indolent [39] and that there may be spontaneous improvement
of neurological symptoms [40], or even spontaneous tumor re-
gression [41, 42]. Some PND presentations such as SN or PLE
tend to react better to therapy than others, such as PCD [6, 8,
43]. For the majority of PND of the CNS, however, therapy is
difficult, and must be started early. Tumor therapy is the main-
stay of therapy, and a complete response to tumor therapy
shows a favorable influence on the course of PND [44].
Immunomodulatory Therapy
Because of current evidence of an autoimmune pathogenesis,
immunomodulatory treatment seems indicated in patients
with paraneoplastic neurological syndromes, although studies
with a high degree of evidence are lacking due to the low
number of patients [1, 2]. However, not all paraneoplastic syn-
dromes respond well to the immunomodulatory options avail-
able so far. For some syndromes, immunomodulatory therapy
rests on sound clinical evidence for its efficacy, such as GBS,
CIDP, LEMS, or stiff-man syndrome.
For the remainder of syndromes – especially of the central
nervous system –, all immunomodultory approaches used so
far do not seem to be very effective on the whole, but may
bring dramatic improvement in single patients. Improvement
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is more likely in PLE or paraneoplastic neuropathy [6, 8, 38].
In general, the earlier immunotherapy is started the better are
the chances of improvement [45, 46].  As immunomodulatory
treatment options protein A absorption, ivIg, cyclophos-
phamide, or plasma exchange have been tried [1, 2, 47, 48].
Due to the uncertain effect, we would start with one course of
i.v. methylprednisolone, such as in MS (5 × 500 mg i.v.), and
wait for a possible effect for one or two weeks. If no effect is
seen we would proceed to one course of ivIg (e.g. 2 g/kg body
weight distributed over 5 days), wait again for a possible ef-
fect, and if no effect is seen maybe proceed to plasma ex-
change or cyclophosphamide according to the individual pa-
tient’s situation.
Concluding Remark
Paraneoplastic neurological syndromes may present with a
varied clinical picture and must be included in nearly any neu-
rological differential diagnosis. As a very helpful tool an ever
growing battery of specific antibodies as paraneoplastic mark-
ers are available for the clinician. With increasing understand-
ing of the autoimmune pathogenesis of these disorders, effec-
tive treatment options besides the oncological therapy may
become available to the patients soon. 
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